tmcnet.com
22-May-2008
250M Potential As its Flurizan product nears what could be a multi-billion dollar market in Alzheimer's disease, Myriad Genetics Inc. launched its global strategy by signing a commercialization deal in Europe with J. Lundbeck AS for $100 million upfront with a potential for $250 million. Myriad...
[read full story]